The DOI matches its Crossref record.
Prevalence of HIV‐1 Drug Resistance after Failure of a First Highly Active Antiretroviral Therapy Regimen in KwaZulu Natal, South Africa
Open accessAbstract
BACKGROUND: Emergence of human immunodeficiency virus type 1 (HIV-1) drug resistance may limit the benefits of antiretroviral therapy in resource-limited settings. The prevalence of resistance was assessed among patients from KwaZulu Natal, South Africa, following failure of their first highly active antiretroviral therapy (HAART) regimen. METHODS: Genotypic resistance testing was performed on plasma virus samples from patients who experienced virologic failure of their first HAART regimen at 2 clinics in KwaZulu Natal. Clinical and demographic data were obtained from medical records. Regression analysis was performed to determine factors associated with > or =1 significant drug resistance mutation. RESULTS: From January 2005 through August 2006, a total of 124 antiretroviral-treated adults who experienced virologic failure were enrolled. The predominant subtype was HIV-1C. Virus samples from 83.5% of participants carried > or =1 significant drug resistance mutation. Dual-class drug-resistant virus was present in 64.3% of participants, and 2.6% had virus with triple-class drug resistance. The most common mutation was M184V/I (64.3% of patients); K103N was present in virus from 51.3%, and V106M was present in virus from 19.1%. Thymidine analog resistance mutations were found in virus from 32.2% of patients, and protease resistance mutations were found in virus from 4.4%. CONCLUSIONS: Antiretroviral drug-resistant virus was detected in >80% of South African patients who experienced failure of a first HAART regimen. Patterns of drug resistance reflected drugs used in first-line regimens and viral subtype. Continued surveillance of resistance patterns is warranted to guide selection of second-line regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Barth, R. E., van der Loeff, M. F. S., Schuurman, R., Hoepelman, A. I., & Wensing, A. M. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70328-7 · Cited by 310
Hosseinipour, M. C., van Oosterhout, J. J., Weigel, R., Phiri, S., Kamwendo, D., Parkin, N., Fiscus, S. A., Nelson, J. A., Eron, J. J., & Kumwenda, J. (2009) · AIDS · doi:10.1097/qad.0b013e32832ac34e · Cited by 288
Gupta, R. K., Hill, A., Sawyer, A. W., Cozzi-Lepri, A., von Wyl, V., Yerly, S., Lima, V. D., Günthard, H. F., Gilks, C., & Pillay, D. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70136-7 · Cited by 254
Magidson, J. F., Joska, J. A., Belus, J. M., Andersen, L. S., Regenauer, K. S., Rose, A. L., Myers, B., Majokweni, S., O’Cleirigh, C., & Safren, S. A. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25720 · Cited by 82
Magidson, J. F., Joska, J. A., Regenauer, K. S., Satinsky, E., Andersen, L. S., Seitz-Brown, C. J., Borba, C. P. C., Safren, S. A., & Myers, B. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2018.11.004 · Cited by 80
Metadata
- Authors
- Marconi, V. C., Sunpath, H., Lu, Z., Gordon, M., Koranteng‐Apeagyei, K., Hampton, J., Carpenter, S., Giddy, J., Ross, D., Holst, H., Losina, E., Walker, B. D., Kuritzkes, D. R., & South Africa Resistance Cohort Study Team
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-05-15
- Volume
- 46
- Issue
- 10
- Pages
- 1589-1597
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2102741140
- Cited by
- 239
- References
- 0
- FWCI
- 18.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence of HIV‐1 Drug Resistance after Failure of a First Highly Active Antiretroviral Therapy Regimen in KwaZulu Natal, South Africa. https://app.cochat.ai/papers/10.1086/587109
- The paper
- Marconi, V. C., Sunpath, H., Lu, Z., Gordon, M., Koranteng‐Apeagyei, K., Hampton, J., Carpenter, S., Giddy, J., Ross, D., Holst, H., Losina, E., Walker, B. D., Kuritzkes, D. R., & South Africa Resistance Cohort Study Team. (2008). Prevalence of HIV‐1 Drug Resistance after Failure of a First Highly Active Antiretroviral Therapy Regimen in KwaZulu Natal, South Africa. Clinical Infectious Diseases. https://doi.org/10.1086/587109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.